Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 1/20 | 0.50 |
| ▸ | CTSK | P43235 | 2/20 | 0.49 |
| ▸ | RPA1 | P27694 | 1/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.41 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | TDO2 | P48775 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dimethylamine SCHEMBL7649217 | 0.89 | ALDH1A1 (0.45) | LMNAADORA2AADORA1MEN1KMT2A | |
| Dimethylamine SCHEMBL7652490 | 0.88 | DHODH (0.52) | CTSKADORA3TP53ADORA2AADORA1 | |
| Dimethylamine SCHEMBL7652894 | 0.87 | ALDH1A1 (0.48) | ADORA3LMNAADORA2AADORA1MEN1 | |
| SCHEMBL7652922 | 0.81 | CTSK (0.50) | MAPK14CTSKRPA1ADORA3TP53 | |
| Dimethylamine SCHEMBL7679157 | 0.79 | ALDH1A1 (0.48) | LMNAMEN1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL7652943 | 0.79 | RPA1 (0.52) | MAPK14CTSKRPA1ADORA3TP53 | |
| Dimethylamine SCHEMBL7656109 | 0.78 | OPRM1 (0.38) | MAPK14ADORA3LMNAADORA2AADORA1 | |
| Dimethylamine SCHEMBL7658435 | 0.78 | ALDH1A1 (0.44) | ALDH1A1DHODH | |
| Dimethylamine SCHEMBL7655386 | 0.77 | ADORA2B (0.43) | MAPK14ADORA3LMNAADORA2AADORA1 | |
| Dimethylamine SCHEMBL7653735 | 0.76 | ALDH1A1 (0.44) | ALDH1A1DHODHNPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6492407-B2 | NEUROPROTECTIVE ACTIVITY | BOEHRINGER IMGELHEIM PHARMA KG (DE) | 2002-12-10 | — | — | US | claimed |
| US-20020045651-A1 | Pharmaceutical compositions containing triazolones and methods of treating neurodegenerative disease using triazolones | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-04-18 | — | — | US | claimed |
| US-6492407-B2 | NEUROPROTECTIVE ACTIVITY | BOEHRINGER IMGELHEIM PHARMA KG (DE) | 2002-12-10 | — | — | US | disclosed |
| US-20020045651-A1 | Pharmaceutical compositions containing triazolones and methods of treating neurodegenerative disease using triazolones | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020045651-A1 | Pharmaceutical compositions containing triazolones and methods of treating neurodegenerative disease using triazolones | PARK7, IAPP, HIF1AN | MAPK14 1293/4885CTSK 1300/4885RPA1 1520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.